baber/WOPTO huggingface dataset:
Patent PT-1992696-E (PT)
Title: Circovirus sequences associated with porcine wasting disease (pwd)
Inventor: JESTIN ANDRÉ
IPC: C12N5/02
Filed: 1998-12-04
Abstract: Nucleotide sequence comprising a 1759 bp genomic DNA sequence (I) of a porcine circovirus called MAP ("maladie de l'amaigrissement du porcelet"; piglet fatal wasting disease), is new. Also claimed are: (1) The nucleotide sequence of the porcine circovirus is: (a) a fragment of (I); (b) a nucleotide sequence homologous to the nucleotide sequence of (a); (c) a nucleotide sequence complementary to (I) or complementary to the nucleotide sequence of (a) or (b); (d) a nucleotide sequence capable of hybridizing under stringent conditions to the nucleotide sequence of (a), (b) or (c); (e) a nucleotide sequence comprising (I) or the nucleotide sequences of (a), (b), (c) or (d); (f) a modified nucleotide sequence comprising the nucleotide sequence of (a), (b), (c), (d) or (e). (2) polypeptide encoded by the nucleotide sequence of (1); (3) cloning and/or expression vectors containing the nucleotide sequences; (4) viral or pseudoviral particles generated from the vectors; (5) host cells transformed with the vectors or (pseudo)viral particles; (6) animals containing the transformed cells; (7) synthetic polypeptides obtained using the amino acid sequence of a polypeptide as in (1); (8) hybrid polypeptides comprising at least one sequence of a polypeptide as in (2) or (7) and a sequence of an immunogenic polypeptide; (9) nucleotide sequences encoding the hybrid polypeptides; (10) vectors containing a sequence as in (9); (11) a method for the detection of the porcine circovirus; (12) mono- or polyclonal antibodies or their fragments or chimeric antibodies capable of specifically recognising a polypeptide as in (2) or (7); and (13) compounds that are capable of binding to a polypeptide or nucleotide sequence as above or of recognising an antibody as in (12) and/or of modulating, inducing or inhibiting the expression of genes and/or of modifying the cellular replication of MAP circovirus or of inducing or inhibiting pathologies associated with MAP circovirus infection in pigs and are capable of being selected by a screening assay comprising contacting a compound with a polypeptide, nucleotide sequence or transformed cell as above or administering the compound to an animal as in (6) and determining the effect of the compound.
Patent PT-2062550-E (PT)
Title: Pocketed hernia repair
Inventor: ROUSSEAU ROBERT A
IPC: A61F2/00
Filed: 2002-03-18
Abstract: A device for surgically repairing and reinforcing a hernia includes a hernia prosthesis having a substantially planar base portion and an overlay portion, each formed from a biocompatible material. The overlay portion is peripherally attached to the base portion to define a pocket to receive a surgical instrument or a surgeon's finger for placing the prosthesis within the human body. The pocket may be formed with releasable stitching to enable it to be flattened or removed after placement and may contain a resilient member that urges the prosthesis into a flat configuration.
Patent PT-2190210-E (PT)
Title: Modular device with status display on the front face, and application
Inventor: GUITARD JULIEN
IPC: H04Q1/02
Filed: 2009-10-28
Abstract: The device has modules arranged on a front face and juxtaposed along an alignment direction (X), where each module has a configuration intervening in a definition of a state of the device and chooses among a predetermined collection of possible configurations. An indicator (2) is assembled rotatably around an axis (X0) of the module, where the indicator is accessed on the front face for selectively placing the indicator in one of stable angular positions representing the configuration of the corresponding module.
Patent PT-2257526-E (PT)
Title: Spiro(5.5)undecane derivatives
Inventor: ENGLBERGER WERNER
IPC: A61K31/437
Filed: 2009-03-25
Abstract: The invention relates to compounds that have an affinity to the μ-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions.
Patent PT-619839-E (PT)
Inventor: GINSBERG MARK H
IPC: C12R1/91
Filed: 1992-12-04
Abstract: Novel polypeptides derived from human fibronectin, and fusion proteins containing those peptide sequences are described which define a receptor binding site on fibronectin that binds to the platelet receptor glycoprotein GPIIb-IIIa expressed by cells. The receptor binding site of human fibronectin includes at least fibronectin amino acid residues 1410-1436. The polypeptides facilitate attachment of cells to substrates either alone or in conjunction with RGD-containing peptides. Vectors preparing the fusion proteins and antibodies are also described. Methods for promoting cell attachment and for inhibiting cell adhesion are also described.
Patent PT-841939-E (PT)
Inventor: ANDREW WILLIAMS NEIL
IPC: A61K39/108
Filed: 1996-07-05
Abstract: There is disclosed the use, as an agent in the treatment or the prevention of an autoimmune disease, of:(i) an agent having GM-1 binding activity, other than Ctx or Etx, or the B subunits of Ctx and Etx; or(ii) an agent having an effect on GM-1 mediated intracellular signalling events, but no GM-1 binding activity.These agents may also be used in the treatment of human T cell leukaemia, in the prevention of transplant rejection or GVHD or in a vaccination method for vaccinating a mammalian subject.
Patent PT-843557-E (PT)
Inventor: ROMAGNANI SERGIO
IPC: A61K35/66
Filed: 1996-07-19
Abstract: The lymphocyte ativation gene (LAG-3) is a member of the immunoglobulin superfamily that is selectively transcribed in human activated T and NK cells. Surface LAG-3 expression correlated with IFN-gamma but not IL-4, production in antigen-stimulated T-cells and it was up-regulated by IL-12 and is preferentially associated with CD4+ T-cells producing Th1-type cytokines. The presence of LAG-3 on the surface of Th1 lymphocytes is used as a marker to detect and identify Th1 lymphocytes and differentiate them from Th2 lymphocytes. Monoclonal antibodies to LAG-3 are used in methods of detecting and isolating Th1 cells as well as methods of diagnosing Th1-mediated disease. The present invention also relates to methods of treating infectious diseases, cancer, and disorders assocated with Th1/Th2 imbalance.
Patent PT-883610-E (PT)
Inventor: PLATZEK JOHANNES
IPC: C07D257/02
Filed: 1997-02-26
Abstract: The invention concerns a process for preparing 1,4,7,10-tetraazacyclododecane (cyclene) and its derivatives on an industrial scale by the cyclotetramerization of benzylaziridine prepared in situ.
Patent PT-964088-E (PT)
Inventor: GSTREIN HIPPOLIT
IPC: B28B21/56
Filed: 1998-10-09
Abstract: Fiber cement felts of the present invention include: a top fabric layer (32) that includes fine machine direction yarns (34) and fine cross machine direction yarns (36) interwoven with the fine machine direction yarns (34), a bottom fabric layer (40) underlying the top fabric layer (32) that includes coarse machine direction yarns (42) and coarse cross machine direction yarns (44) interwoven with the coarse machine direction yarns (42), and a batt layer (50) attached to and overlying the top fabric layer (32). Preferably, the top fabric layer (32) is heat bonded to the bottom fabric layer (40). It is also preferred that the fiber cement felt of the present invention include a second batt layer (52) that underlies the bottom fabric layer (40). In this multiple layer structure, the felt can have higher tenacity, improved resistance to blinding and compaction, and a reduced tendency to mark a fiber cement sheet during its formation.   <IMAGE>
Patent PT-937829-E (PT)
Inventor: HEINZMANN GOTTFRIED
IPC: E03C1/322
Filed: 1999-02-06
Abstract: For fixation the two components (1,7) are connectable to one another by means of a screw connection (17). They are provided with recesses (3,10) which the screw connection penetrates. The first component (1) has a recess (5) penetrable by a wall-side screw (12) fixing the wash stand. At least one of the recesses receiving the screw connection has an inner thread. The first component has a first section (2) with the recess (3) accommodating the screw connection and a second section with the recess accommodating the wall-side screw. The sections are arranged particularly at an angle of 65 degrees to each other.
Patent PT-978493-E (PT)
Inventor: FRIEDRICH SIEBERS DR
IPC: C03C8/02
Filed: 1999-07-09
Abstract: A lead- and cadmium-free borosilicate glass, having a specified composition and having a low thermal expansion coefficient, is new. A low thermal expansion coefficient lead- and cadmium-free glass, for glass coating, enameling and decorating glasses or glass-ceramics, has the composition (by wt.) 0-6 % Li2O, 0-5 % Na2O, 0 to less than 2 % K2O, 2-12 % Li2O + Na2O + K2O, 0-4 % MgO, 0-4 % CaO, 0-4 % SrO, 0-1 % BaO, 0-4% ZnO, 3 to less than 10 % Al2O3, 13-23 % B2O3, 50-65 % SiO2, 0-4 % TiO2, 0-4 % ZrO2, 0-4 % F (substituting for oxygen) and up to 30 % firing temperature resistant pigment. An Independent claim is also included for processes for producing a glass-ceramic which is coated, enameled and decorated with the above glass.
Patent PT-987256-E (PT)
Inventor: HEDTMANN UDO
IPC: C07D261/18
Filed: 1998-07-31
Abstract: Crystal modification 2 of N-(4-trifluoromethylphenyl)-5-met hylisoxazole-4-carboxamide (I) (leflunomid; HWA 486) is new. - New crystal modification 2 of N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide (I) has lines (diffraction angles 2theta ([deg])) of strong intensity at 10.65, 14.20, 14.80, 16.10, 21.70, 23.15, 24.40, 24.85, 25.50, 25.85, 26.90 and 29.85 and of medium intensity at 7.40, 9.80, 13.10, 15.45, 16.80, 20.70, 21.45, 22.80, 23.85, 27.25 and 28.95 in the X-ray diffraction graph using Cu-Kalpha 1 radiation in the focusing Deybe-Scherrer procedure and transmission. Compound (I) is known from US 4284786. Independent claims are included for: (A) the preparation of crystal modification 2; and (B) the preparation of crystal modification 1 of compound (I) having lines of strong intensity at 16.70, 18.90, 23.00, 23.65 and 2.05 and lines of medium intensity at 8.35, 12.65, 15.00, 15.30, 18.35, 21.55, 24.10, 24.65, 25.45, 26.65, 27.40, 28.00 and 28.30 in the X-ray diffraction graph measured and defined in the same manner as for crystal modification 2. -
Patent PT-985895-E (PT)
Inventor: SAUERBERG PER
IPC: F28F1/30
Filed: 1999-09-08
Abstract: The invention relates to a heat exchanger unit to be used in a gas-fired water heater in which heater a heat exchanger unit contains tubes with fins. According to the invention the heat exchanger unit contains flat oval tubes (1,21,31) having a fin (3,22,32) at least on one flat part (4,24,33). The flat oval tubes (1,21,31) as well as the fins (3,22,32) are made of copper, copper-based alloy, aluminium or aluminium-based alloy. <IMAGE>
Patent PT-1133697-E (PT)
Inventor: ILAG L LEODEVICO
IPC: G01N33/533
Filed: 1999-11-23
Abstract: The invention relates to a method for identifying one or more functional sites in proteins. Said method is characterized by the following steps: a) contacting the target protein with a binding partner (BP tag) linked with a laser-activatable marker (tag), resulting in a complex consisting of target protein and BP tag, b) irradiating the complex consisting of target protein and BP tag with laser light, resulting in the formation of free radicals which selectively modify the bound target protein at the binding site, and c) identifying the selectively modified region of the protein by a combination of protein cleavage and mass spectrometry. The invention further relates to a device for carrying out the inventive method.
Patent PT-1058544-E (PT)
Inventor: DAN ADERKA
IPC: A61P3/10
Filed: 1999-12-30
Abstract: The bioactivity of TNF is inhibited by administering heparin or a derivative thereof along with a soluble TNF receptor. The heparin or derivative thereof can be administered simultaneously with the soluble TNF receptor, either in separate compositions or in compositions containing both heparin or a derivative thereof and at least one soluble TNF receptor. The heparin or derivative may also be administered without the soluble TNF receptor and still effect some amount of inhibition of TNF bioactivity.
Patent SG-20392-G (SG)
Title: Process for regenerating a carbonylation catalyst solution to remove corrosion metals
IPC: B01J31/40
Filed: 1992-02-29
Abstract: A process for treating carbonylation catalyst solutions which contain a rhodium component and a lithium component to remove metallic corrosion products comprises contacting the catalyst solution with a cation exchange resin in the lithium form.
Patent SG-44691-G (SG)
Title: Shearing type blowout preventer
IPC: E21B33/06
Filed: 1991-06-15
Abstract: A ram-type shearing apparatus for a wellhead having a body with a vertical bore therethrough and aligned, opposed ram guideways 16 extending outward in the body from the bore, a ram assembly 20, 22 in each of the guideways, each of the ram assembles having a ram body with a shearing blade 36, 38 on the face of the ram and means for moving the ram inward and outward in the guideway, the cutting edge of the upper shear blade 38 and the face of the ram assembly below the upper shear blade being concave to support the string during shearing sufficiently to constrain the string below the upper shear blade as it is sheared to a shape suitable for receiving an overshot type of retrieving tool and to allow flow therein, the lower shear blade 36 having at least one node extending toward the upper shear blade so that when a pipe is being sheared the node engages and penetrates the pipe prior to other shearing of the pipe to thereby reduce the force used for such shearing.
Patent IE-780460-L (IE)
Title: Tapping gas form a cartridge
IPC: F17C7/00
Filed: 1978-03-07
Abstract: In a device for tapping gas from a gas-containing cartridge, there is provided a screw socket into which a threaded end of a tap forming part of a gas-using appliance is screwed, a piston spring-loaded in the direction of the end of the socket and bearing at its end sealing means engaging the cartridge, a perforating needle mounted on the socket and extending through the piston, and stop means to limit the travel of the piston under the action of its spring. The piston is hollow and of larger diameter than the socket which latter extends into a bore in the piston, the piston sliding over and outside the socket. By this means, the risk of seizure of the piston in prolonged use of the device is considerably reduced. (From US4177828 A) [FR2383389A1]
Patent IE-810490-L (IE)
Title: Centrifugal pump
IPC: F04D7/04
Filed: 1981-03-06
Abstract: PCT No. PCT/GB81/00035 Sec. 371 Date Nov. 4, 1981 Sec. 102(e) Date Nov. 4, 1981 PCT Filed Apr. 4, 1981 PCT Pub. No. WO81/02613 PCT Pub. Date Sep. 17, 1981.A pump, for example, a centrifugal slurry pump, has a casing (10) with an inlet (12) and an outlet (14). The casing (10) and a separate backliner (28) define a chamber (16) in which an impeller (18) is arranged to be rotated by way of a drive shaft (20) which extends axially with respect to the casing (10). Fine running clearances are defined between the front and rear surfaces of the impeller (18) and the adjacent surfaces of the casing (10) and the backliner (28). In order to compensate for increases of the running clearances, for example, due to erosion, the backliner (28) may be moved axially relative to the casing (10). The backliner (28) is connected to an annular flange (38) which is bolted to an annular flange (36) connected to the casing (10) and the spacing between the flanges (36, 38) may be adjusted by removing one or more shims (40) provided therebetween.
[US4521151A]
Patent IE-860543-L (IE)
Title: Concrete pile section
IPC: E04B1/21
Filed: 1986-02-28
Abstract: A pile section for a sectional pile including a string of sections includes a concrete member (10) having at least one longitudinally reinforcing rod (12), the rod including a spigot (14) at one end and a socket (18) at the other which in use are adapted for permanent interconnection so that on driving one section against its neighbor a continuous reinforcing element is provided.
Patent IE-40379-L (IE)
Title: Cellulosic bodies incorporating enzymes
IPC: C12N11/04
Filed: 1974-03-15
Abstract: To obtain cellulosic fibres containing enzymes, capable of displaying a catalytic activity in enzymatic reactions, a substituted cellulose derivative is dissolved in a water-insoluble solvent. An aqueous solution of the enzyme is then added to the solution, and the emulsion is subjected to spinning and coagulation conditions. Finally, the fibre obtained is treated with a reducing agent, in order to remove the substituent under operating conditions which do not damage the enzyme. The substituted cellulose derivative can, for example, be nitrocellulose. In this case, the reducing agent is a solution of ammonium sulphide. The said substituted cellulose derivative is dissolved in a water-insoluble solvent selected from normal-butyl acetate, dibutyl phthalate, methyl amyl ketone and ethyl amyl ketone. The enzyme used is selected from uricase, invertase, lactase, acylase, transaminase, glucose oxidase, catalase, papain, tryptophan synthetase and penicillin amidase. This gives cellulose fibres having a permeability very much higher than that of the same fibres based on substituted cellulose.
[GB1453744A]
Patent IE-780614-L (IE)
Title: Air freshener formulations stabilized with an alkyl phenoxy¹polyethoxy alcohol
IPC: A61K8/00
Filed: 1978-03-29
Abstract: ALKYL PHENOL ETHER OF POLYETHYLENE GLYCOL AS STABILIZER OF AIR FRESHENER Compositions of fragrance oils are stabilized with respect to potency and aesthetic quality toward the effects of heat and age by including in the formulations a quantity of alkylphenol ethers of polyethylene glycol, or more specifically, alkyl phenoxy polyethoxy ethanols wherein the polyether chain averages from 5 to 13 moles of ethylene oxide, and the alkyl portion of the molecule ranges from 6 to 20 carbon atoms. The alkyl portion of the molecule may be branched, unbranched, saturated or unsaturated. The oils are stabilized in respect to durability or intensity of odor with time and are rendered relatively insensitive to the deleterious effects of heating and/or aging in the presence of air. The presence of the stabilizers also eliminates the phenomenon of the "migration" of the perfume oil caused by repeated vaporization and condensation within an enclosed space. In addition, the inclusion of the stated stabilizers, when judiciously used, tends to "round out" or "smooth out" the overall perception of the odor characteristics of the particular oils utilized, often increasing the aesthetic value of the fragrance composition when so used.
[CA1096311A]
Patent IE-39348-L (IE)
Title: Bottom-dump vessel
IPC: B63B25/04
Filed: 1974-03-25
Abstract: A bottom-dump vessel having two longitudinal hull sections forming air cases or pontoons hinged together for movement about a longitudinal axis. An intermediate section arranged at least partially in a recess between the two longitudinal hull sections. The intermediate section is hinged with port and starboard hinges to the two longitudinal hull sections.
[US3918381A]
Patent IE-34315-L (IE)
Title: Sealing overlapped foam plastics sheets.
IPC: B29C65/00
Filed: 1970-06-17
Abstract: 1,265,923. Seaming non-metallic sheet material. STICHTING ONTWIKKELING VERPAKKINGSMETHODEN IN DE ZUIVELINDUSTRIE. 18 June, 1970 [18 June, 1969], No. 29592/70. Heading B5K. One or more thermoplastic foam films or foam sheets with a density below 250 kg. per cubic meter, preferably below 100 kg. per cubic meter, are sealed by overlapping the films or sheets without a bonding agent therebetween, enclosing the films or sheets at least substantially on all sides in dies 1, 2, 7, 8 adapted to compress them at a temperature above the softening point of the plastics material, foaming again the compressed product at the same temperature by decreasing the pressure, and sealing at a predetermined foam thickness by cooling at least one side. Preferably, the pressure is decreased by increasing the distance between the die sections until a predetermined foam thickness is reached. The pressure applied to the films or sheets enclosed in the dies is at least 2 kg. per square cm. If the films or sheets consist of polystyrene foam having a density of 40 kg. per cubic m., they are sealed at a pressure of 4 kg. per sq. cm. and a temperature of 120-130‹ C., e.g. 128‹ C. In another example, two cross-linked polypropylene foam sheets having a density of 70 kg. per cubic m. are sealed in 4 seconds at a pressure of 20 kg. per sq. cm. at a die temperature of 185‹ C. Other specified foam plastics compositions are polystyrene-rubber compositions, polyvinyl chloride, copolymers of vinyl derivatives, polyethylene and polypropylene and their copolymers and acrylonitrile-butadiene-styrene compositions. A container, Figs. 1 and 2, is made by folding a foam plastics blank 9 about a heated mandrel 1 with the upper flaps 11, 12, 13, 14 folded as shown in Fig. 2. The external planes of the blank are enclosed and compressed by heated die halves 7, 8 and a heated plunger 2. The pressure is reduced and the distance between the parts 2, 7, 8 and the mandrel 1 is increased to allow foaming. Cooling is then effected either by cooling the parts 2, 7, 8 or by removing these parts and shifting the mandrel 1 to another position in which cold or cooled parts 2, 7, 8 are applied to the blank.
[GB1265923A]
Patent IE-35401-L (IE)
Title: Dentrifices
IPC: A61K/
Filed: 1971-06-24
Abstract: 1309209 Dentifrice containing iridescent and pearlescent flakes COLGATE-PALMOLIVE CO 14 June 1971 [13 July 1970] 27687/71 Heading A5B Dentifrice, having a sparkingly appearance and improved stain-removing properties contain non-toxic iridescent or pearlescent flakes such as mother of pearl flakes or iridescent mica flakes coated with another material, whose refractive index is different from that of mica e.g. titanium dioxide or BiOCl. The dentifrice may contain 0.1 to 5% by weight of the flakes and may be in the form of a transparent paste, gel or cream, powder or tablet. The dentifrice may also contain water, a humectant such as glycerine, sorbitol, propylene glycol or polyethylene glycol; a gelling agent such as sodium carboxymethyl cellulose and/or synthetic finely divided silicas; a polishing agent such as sodium aluminosilicate and/or amorphous silicic anhydride; a surface agent e.g. sodium lauryl sulphate; a colouring or whitening agent; a preservative such as sodium benzoate; a silicone; a chlorophyll compound; an ammoniated material such as urea and/or diammonium phosphate; or anti-bacterial agent; a flavouring or sweetening sialagogue e.g. saccharin or chloroform; and/or a fluorine-containing compound.
Patent IE-33225-L (IE)
Title: Tyre ply
IPC: B60C9/00
Filed: 1969-07-14
Abstract: 1276852 Pneumatic tyres DUNLOP HOLDINGS Ltd 15 July 1969 [16 July 1968] 33745/68 Heading B7C A radial or cross ply pneumatic tyre has a carcass comprising one or more plies of steel cord fabric, the cords being made up of individual wires each having a diameter of no more than 0-003 inch and preferably less than 0À0016 inch. The cords may each comprise two yarns, and have a twist of 7¢ turns per inch. The cord spacing, measured perpendicular to the cords length, may be 15 cords per inch. The ratio of sectional height measured from the bead base to the radially outermost part of the crown to the maximum axial width is no greater than 0À90. Specifications 1,259,600, 1,266,861, 1,276,853, 1,276,854 and 42261/68 (co-pending) are referred to.
[GB1276852A]